C R Bard (BCR) Earns News Impact Rating of 0.29

News articles about C R Bard (NYSE:BCR) have been trending positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. C R Bard earned a daily sentiment score of 0.29 on Accern’s scale. Accern also gave news headlines about the medical instruments supplier an impact score of 45.2927102459399 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of C R Bard (NYSE BCR) traded down $1.95 during trading on Friday, reaching $331.24. 4,714,800 shares of the company’s stock traded hands, compared to its average volume of 679,456. C R Bard has a 52 week low of $222.42 and a 52 week high of $337.73. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37. The stock has a market cap of $24,140.00, a P/E ratio of 43.64, a P/E/G ratio of 2.53 and a beta of 0.52.

C R Bard (NYSE:BCR) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.96 by $0.06. C R Bard had a net margin of 9.51% and a return on equity of 19.39%. The company had revenue of $989.80 million for the quarter, compared to the consensus estimate of $990.64 million. During the same period last year, the firm posted $2.64 EPS. C R Bard’s revenue for the quarter was up 5.1% on a year-over-year basis. sell-side analysts anticipate that C R Bard will post 11.89 earnings per share for the current year.

Several equities research analysts recently commented on BCR shares. Zacks Investment Research upgraded shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price target on the stock in a research note on Tuesday, December 26th. Cowen reiterated a “hold” rating and set a $317.00 price target on shares of C R Bard in a research note on Friday, November 3rd. Needham & Company LLC reiterated a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th. ValuEngine downgraded shares of C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Barclays raised their price objective on shares of C R Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research report on Monday, November 6th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $311.43.

In other C R Bard news, Director David M. Barrett sold 3,344 shares of the firm’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $327.31, for a total transaction of $1,094,524.64. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Frank Lupisella, Jr. sold 7,035 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $334.70, for a total transaction of $2,354,614.50. Following the transaction, the vice president now directly owns 13,824 shares in the company, valued at $4,626,892.80. The disclosure for this sale can be found here. Insiders have sold a total of 114,602 shares of company stock worth $38,193,867 over the last three months. 0.80% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “C R Bard (BCR) Earns News Impact Rating of 0.29” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/19/c-r-bard-bcr-earns-news-impact-rating-of-0-29.html.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply